Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Research Suggests How Tumors Evolve to Become Aggressive Form of Prostate Cancer

The genetic changes that underlie an especially lethal type of prostate cancer have been revealed in a new study by investigators at Weill Cornell Medicine. Learning more about what causes this type of cancer, called neuroendocrine prostate cancer (NEPC), could lead to new approaches for treating it.

Most early-stage prostate cancers require male hormones (androgens) like testosterone to grow. However, as they advance, they may evolve into castration-resistant prostate cancer (CRPC), a type that can grow without hormones and is harder to treat. NEPC is one type of CRPC.  The findings, published June 7 in Nature Communications, revealed important findings about the basic biological actions that lead to this cancer. Dr. Nicholas Brady, an instructor in Pathology and Laboratory Medicine, and Dr. Alyssa Bagadion, a Weill Cornell Graduate School doctoral student in the Rickman lab at the time of the study, are co-first authors on the study.

Read the full article here. 

source: Weill Cornell Medicine